Cannabis
Garden Of Life® Introduces First Line Of CBD Formulas Certified THC-Free By Labdoor, The First-Of-Its-Kind Third-Party Authentication
Garden of Life® announces the launch of its cannabidiol (CBD) line, the industry’s first and only to be THC-Free Certified by Labdoor, providing absolute assurance for consumers seeking CBD products without psychoactive effects. Made from Broad Spectrum Whole Hemp Extract, the new Garden of Life Dr. Formulated CBD formulas contain a naturally occurring complex of cannabinoids, terpenes and fatty acids without THC (tetrahydrocannabinol). In addition, all of the products are Certified Non-GMO and gluten-free.
“There are a lot of unfamiliar terms and claims out there as more people seek out CBD products, and Labdoor’s THC-free certification cuts through the clutter, providing absolute certainty around our products,” said Garden of Life President Brian Ray. “As the leader in traceable, third-party certified nutrition solutions, we’re proud to be first in the industry to partner with Labdoor in bringing this line to market.”
THC-free Certified by Labdoor is the industry’s only third-party certification around the presence of THC in hemp-derived products, such as CBD. Labdoor’s new certification tests all CBD products before they are sold, and verifies the purity and potency of supplements and CBD products through its Quality Certification. To earn Certification, products must prove through testing that their active ingredient content always matches their label claims and that all products are free of heavy metals or microbiological contamination. These two certifications combine to answer consumers’ biggest questions about product safety and quality.
“Labdoor certifies each lot of Garden of Life’s CBD ingredients and finished products to ensure supply chain security,” said Neil Thanedar, chief executive officer of Labdoor. “Informed consumers increasingly expect all of their products to be certified by independent organizations like Labdoor, and Garden of Life’s commitment to this advanced proficiency testing will help make these certifications an industry-wide standard.”
Studied and formulated by experts
To create the CBD line, Garden of Life worked with David Perlmutter, M.D., America’s leading neurologist. Dr. Perlmutter is a New York Times best-selling author, leader in the study of the human microbiome and the driving force behind all Dr. Formulated products.
“Garden of Life is taking CBD formulation to the next level and these products will set the standard in the field. Made from the safest, cleanest and most trusted ingredients available, this new line opens up a world of possibilities for people seeking the therapeutic benefits of CBD, without the worry of any THC being ingested in the body,” said Dr. Perlmutter.
Garden of Life Dr. Formulated CBD formulas
The following products are offered in liquids, non-GMO softgels and sprays, at retailers across the country.
CBD Liquid Drops
- Dr. Formulated Whole Hemp Extract liquids are stand-alone formulas available in three dosage strengths: 10mg, 30mg and 50mg. They include specially sourced Pure Essential Oils rich in terpenes, to create a more potent entourage effect. The liquid formulas come in two organic flavors: chocolate mint and peppermint.
- Dr. Formulated CBD + Stress Relief † liquid delivers 15mg CBD with clinically studied Extramel® French melon SOD. Short for superoxide dismutase, SOD is a powerful enzyme and potent antioxidant that has been studied and shown to help manage stress.† A clinically studied dose of 140IU SOD is added per serving.
- Dr. Formulated CBD + Inflammatory Response † delivers 15mg CBD along with clinically studied Astaxanthin. The essential oils blend includes organic oils of ginger, orange, rosemary, lemongrass and eucalyptus.
- Dr. Formulated CBD + Sleep liquid provides 15mg CBD with added organic lemon balm, lavender and chamomile herbs to aid falling asleep.†
- Dr. Formulated CBD + Youthful Skin † liquid delivers 15mg CBD with organic lipowheat. A team of French scientists researched and developed this phytoceramide, lipid from wheat. Phytoceramides play a central role in preserving healthy-looking skin.†
- Dr. Formulated CBD Pet provides 20mg CBD from Whole Hemp Extract in a peanut butter flavor.
CBD PlantGel Softgels
Garden of Life created the industry’s first Non-GMO Certified softgels for the Dr. Formulated CBD products.
- Dr. Formulated CBD Whole Hemp Extract is available in servings of 10mg or 30mg of CBD. The small, easy-to-swallow softgel is formulated with CBD from Whole Hemp Extract, as well as Pure Essential Oils rich in terpenes, to create a more potent entourage effect.
- Dr. Formulated CBD + Relax delivers 15mg CBD along with 50mg L-Theanine from organic green tea extract (98 percent) with 30mg organic saffron and L-Theanine, ingredients that may promote relaxation and a sense of calm.†
- Dr. Formulated CBD + Turmeric provides 15mg CBD per serving along with an Inflammatory Response Blend with organic turmeric extract (50mg curcuminoids) plus ginger extract (root) extract with 10 percent gingerols and organic black pepper extract fruit (5mg). The blend of essential oils contains organic clove oil with rosemary leaf oil and organic black pepper fruit oil
- Dr. Formulated CBD + Sleep provides 15mg CBD along with 1200IU vitamin D3 to support sleep.† In addition to including significant amount of vitamin D3, the formula includes a sleep support blend with lemon balm, valerian and chamomile extracts, organic clove oil with rosemary leaf oil and organic black pepper fruit oil.
- Dr. Formulated CBD + DHA delivers 15mg CBD and a Hemp Extract Blend with 500mg DHA plus 1200IU vitamin D3, which is important for overall brain health.†
CBD Spray
- Dr. Formulated CBD Whole Hemp Extract Spray delivers 5mg CBD per serving from whole hemp extract, plus specially sourced Pure Essential Oils rich in terpenes for a more potent entourage effect. It features a delicious chocolate mint taste.
How CBD products work
Cannabinoids are chemical compounds naturally found in the human body and also in hemp (cannabis) plants. Cannabinoids interact with receptors in the body to restore a normal state of healthy balance.
The cannabidiol, or CBD, present in hemp is not a psychoactive compound and will not produce a “high” effect unless it contains THC. All Garden of Life Dr. Formulated THC-free Labdoor Certified CBD products are made from American-grown hemp using a clean extraction process that is free from solvents and harsh chemicals.
“In light of the recent research regarding potential benefits of CBD, and the passage of the Farm Bill in 2018 legalizing industrial hemp containing less than 0.3 percent THC by dry weight, there has been tremendous consumer demand for CBD products,” Ray added. “Our new formulas are ideal for consumers who want the benefits of CBD without the effects or implications of THC.”
To learn more, visit www.gardenoflife.com.
SOURCE Garden of Life
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
